Carboplatin을 포함한 항암제 투여환자에서 유발된 오심, 구토에 대한 palonosetron과 ramosetron의 항구토효과 비교
A Comparison between Palonosetron and Ramosetron in Antiemetic Effect in Patients Administered with Carboplatin-containing Anticancer Drugs
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
About 70 to 80% of patients who undergo chemotherapy experience chemotherapyinduced nausea and vomiting (CINV), which is one of the most common and important adverse events that affect the quality of life. Palonosetron, one of 5-HT3 receptor antagonists (5-HT3RAs), is used to prevent acute and delayed CINV as the only second-generation drug Between June and September 2009, 103 patients were administered with anticancer drugs containing carboplatin. Among them, patients with cervical, ovarian cancer and non-small cell lung cancer who were treated with carboplatin-paclitaxel or carboplatin-docetaxel, became the subjects of this study. This study was retrospectively performed, and the subjects were classified into two groups, the ramosetron group (R-Group; n=32) and the palonosetron group (P-Group; n=18). The two groups were compared to each other in antiemetic effect and cost. Patients who experienced CINV at least once accounted for 29% and 34% in P-Group and R-Group respectively. 50.9% of P-Group and 45.7% of R-Group took the additional antiemetic drugs. In relation to the cost of antiemetic drugs, P-Group costed a tenth part compared to R-Group. Also, the cost of adding antiemetics above the drugs included in the regimen, P-Group costed 1/3 less compared to R-Group(p=0.004). In conclusion, palonosetron is as effective as the first-gen-eration of 5-HT3 RAs in frequency of emetogenicity. It is expected to be a useful antiemetic in the points of cost-effectiveness and ease of administration. However, this study was conducted on a small number of patients during a short period, thus it was problematic to evaluate the efficacies. A prospective study needs to be performed, excluding other factors that may influence nausea and vomiting.
Abstract
About 70 to 80% of patients who undergo chemotherapy experience chemotherapyinduced nausea and vomiting (CINV), which is one of the most common and important adverse events that affect the quality of life. Palonosetron, one of 5-HT3 receptor antagonists (5-HT3RAs), is used to prevent acute and delayed CINV as the only second-generation drug Between June and September 2009, 103 patients were administered with anticancer drugs containing carboplatin. Among them, patients with cervical, ovarian cancer and non-small cell lung cancer who were treated with carboplatin-paclitaxel or carboplatin-docetaxel, became the subjects of this study. This study was retrospectively performed, and the subjects were classified into two groups, the ramosetron group (R-Group; n=32) and the palonosetron group (P-Group; n=18). The two groups were compared to each other in antiemetic effect and cost. Patients who experienced CINV at least once accounted for 29% and 34% in P-Group and R-Group respectively. 50.9% of P-Group and 45.7% of R-Group took the additional antiemetic drugs. In relation to the cost of antiemetic drugs, P-Group costed a tenth part compared to R-Group. Also, the cost of adding antiemetics above the drugs included in the regimen, P-Group costed 1/3 less compared to R-Group(p=0.004). In conclusion, palonosetron is as effective as the first-gen-eration of 5-HT3 RAs in frequency of emetogenicity. It is expected to be a useful antiemetic in the points of cost-effectiveness and ease of administration. However, this study was conducted on a small number of patients during a short period, thus it was problematic to evaluate the efficacies. A prospective study needs to be performed, excluding other factors that may influence nausea and vomiting.
참고문헌 (14)
- Navari R.M, "Antiemetic control: toward a new standard of care for emetogenic chemotherapy", Expert Opin Pharmacotherapy, 10(4), pp.629~644 (2009)
- Sato M, "Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double- blind, double-dummy, randomized, comparative phase III trial", Lancet Oncol, 10, pp.115~124 (2009)
- Navari R.M, "Pharmacological management of chemotherapy-induced nausea and vomiting focus on recent developments", Drugs, 69(5), pp.515~533 (2009)
- Gralla R, "Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron", Ann Oncol, 14(10), pp.1570~1577 (2003)
- Eisenberg P, "Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically Novel 5-HT3 receptor antagonist: results of a Phase III, Single-Dose Trial Versus Dolasetron", Cancer, 98(11), pp.2473~2482 (2003)
- Navari R.M, "Palonosetron a second generation 5-hydroxytryptamine 3 receptor antagonist", Expert Opin Drug Metabolism & Toxicology, 5(12), pp.1577~1586 (2009)
- Aapro M.S, "Palonosetron as an anti-emetic and anti-nausea agent in oncology", Ther Clin Risk Manag, 3(6), pp.1009~1020 (2007)
- Grunberg S.M, "Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis", Annals of Oncology, 18, pp.233~240 (2007)
- Pradelli L, "Palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in Italy: pharmacologic, clinical and economic aspects", Tumori, 94(2), pp.26~32 (2008)
- Rojas C, "Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function", European Journal of Pharmacology, 626, pp.193~199 (2010)
- Tian W, "Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapyinduced nausea and vomiting in a Chinese population", Med Oncol (2010)
- Musso M, "Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multipleday chemotherapy", Support Care Cancer, 17(2), pp.205~209 (2009)
- "NCCN clinical practice guidelines in oncology", ~ (2009), v.4